September 27, 2022
Loading...
You are here:  Home  >  Latest news  >  Current Article

Amgen stock stable despite end of drug ban

IN THIS ARTICLE

Shares for Amgen have remained relatively stable amid news that sales of a rival drug would be allowed and a cash and stock partnership deal with Bay Area-based CytomX. The Thousand Oaks biotech giant partnered up with Bay Area-based CytomX Therapeutics to develop an anti-cancer drug, purchasing $20 million of its common stock. Two days…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.